Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials

Fig. 1

Changes from baseline in disease activity up to month 12. LS mean change from baseline in a DAS28-4(ESR) and b CDAI to month 12 across treatment groupsa pooled from Phase 3 ORAL Scan, ORAL Standard, and ORAL Sync study datasets (full analysis set). aAll treatments were administered in combination with background conventional synthetic disease-modifying antirheumatic drugs. *** p < 0.001 for tofacitinib and adalimumab vs placebo; p < 0.05 and †† p < 0.01 for tofacitinib vs adalimumab. The horizontal dashed lines represent the MCIDs. The arrows on the y-axes indicate the direction of improvement. ADA, adalimumab; BID, twice daily; CDAI, Clinical Disease Activity Index; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; LS, least squares; MCID, minimum clinically important difference; Q2W, once every 2 weeks; SE, standard error

Back to article page